Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,233 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Pulmonary Disease COPD Clear all
Completed Phase 2 Interventional

Pilot Study of the Spiration IBV™ System

NCT00145548
View directory record Official record
Conditions
Emphysema
Interventions
Intra Bronchial Valve
Device
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
18 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
14
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 15, 2026, 9:27 AM EDT
Recruiting Not applicable Interventional

Physiologic Effects of Nasal High Flow on Exercise Tolerance in COPD

NCT06578156
View directory record Official record
Conditions
COPD
Interventions
Nasal High Flow Cannula, Nasal Low Flow Cannula
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Not applicable Interventional

Healthy Mediation Adherence To Transform and Effectively Relieve Symptoms

NCT04656093
View directory record Official record
Conditions
COPD, Diabetes, Hypertension
Interventions
Supportive counseling, Education on SMB, Psychoeducation on ATs for maladaptive beliefs (if applicable), Psychoeducation on emotional response (if applicable)
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 15, 2026, 9:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Developing a COPD Case Finding Methodology for Primary Care

NCT01880177
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
40 Years and older
Enrollment
346 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
4
States / cities
Lexington, Kentucky • Ann Arbor, Michigan • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 15, 2026, 9:27 AM EDT
Terminated Not applicable Interventional

Telemedicine for Improving Outcome in Inner City Patient Population With Hypercapneic Respiratory Failure

NCT03353064
View directory record Official record
Conditions
Hypercapnic Respiratory Failure, Chronic Obstructive Pulmonary Disease, Obesity Hypoventilation Syndrome, Sleep Disordered Breathing, Neuromuscular Diseases
Interventions
Vivify, EMS
Other
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00606684
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GW642444 6.25, GW642444 3mcg, GW642444 12.5mcg, GW642444 25mcg, GW642444 50mcg, placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
49
States / cities
Florence, Alabama • Jasper, Alabama • Montgomery, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease

NCT01323634
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg/ salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
12
States / cities
Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Not applicable Interventional

Abdominal Functional Electrical Stimulation to Reduce Hyperinflation in Chronic Obstructive Pulmonary Disease Patients

NCT02035228
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Abdominal Stimulation - low / early, Abdominal stimulation - low/late, Abdominal Stimulation - low/full, Abdominal stimulation - med/early, Abdominal stimulation - med/late, Abdominal Stimulation - med/full, Abdominal Stimulation - high/early, Abdominal Stimulation - high/late, Abdominal Stimulation - high/full
Device
Lead sponsor
Liberate Medical
Industry
Eligibility
40 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 15, 2026, 9:27 AM EDT
Terminated No phase listed Observational

Use Of Capnography As Surrogate Measure Of PC02 In Medical Intensive Care Unit (ICU) Patients

NCT00744614
View directory record Official record
Conditions
Asthma, Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease
Interventions
Capnography
Procedure
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2010 · Synced Oct 15, 2026, 9:27 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies

NCT01776398
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Idiopathic Pulmonary Fibrosis (IPF), Rheumatoid Arthritis-Associated Interstitial Lung Disease, Scleroderma-Associated Interstitial Lung Disease (SSC-ILD)
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 4 Interventional Results available

A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03474081
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/UMEC/VI, Tiotropium, Albuterol/salbutamol, Placebo to match FF/UMEC/VI, Placebo to match tiotropium, ELLIPTA inhaler, HANDIHALER, MDI
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
33
States / cities
Andalusia, Alabama • Huntington Beach, California • Sacramento, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pathogenesis and Outcomes of Sleep Disordered Breathing in Chronic Obstructive Pulmonary Disease (COPD)

NCT01764165
View directory record Official record
Conditions
COPD
Interventions
Oxygen, High flow of room air
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 1 Interventional

Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device

NCT06254664
View directory record Official record
Conditions
COPD
Interventions
Tiotropium 18 µg inhalation powder, hard capsule, Zephir inhaler
Drug · Device
Lead sponsor
Xiromed LLC
Industry
Eligibility
40 Years to 75 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Fort Myers, Florida • Kissimmee, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 2 Interventional

Dose-Ranging Study of A006 DPI, in Adult Asthma Patients

NCT01174732
View directory record Official record
Conditions
Asthma, Bronchospasm
Interventions
albuterol inhalation powder, Placebo, albuterol inhalation aerosol
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
San Jose, California • Centennial, Colorado • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 15, 2026, 9:27 AM EDT
Terminated Not applicable Interventional

Evaluating Genes in Sputum to Measure Drug Response in COPD

NCT00233051
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
Interventions
Salmeterol or Salmeterol/Fluticasone
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Not applicable Interventional Results available

IVR-Enhanced Care Transition Support for Complex Patients

NCT01135381
View directory record Official record
Conditions
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions
IVR-Enhanced Care
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Oct 15, 2026, 9:27 AM EDT
Completed No phase listed Observational

Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation

NCT07414134
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
BGF- BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
3,598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Gaithersburg, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Not applicable Interventional

Monitoring Metered Dose Inhalation (MDI) Volume and Timing With a Respimetrix Device in Obstructive Lung Disease.

NCT05495256
View directory record Official record
Conditions
Asthma, Copd
Interventions
Respimetrix
Device
Lead sponsor
Pulmonary Critical Care Associates of Baltimore
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease

NCT02662582
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Reldesemtiv, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Torrance, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 15, 2026, 9:27 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Safety Study of Nebivolol for COPD Patients

NCT01939990
View directory record Official record
Conditions
High Blood Pressure
Interventions
Placebo, Nebivolol
Drug
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

NCT00696020
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BI 1744 CL/tiotropium bromide fixed dose combination, tiotropium bromide, Respimat® Inhaler
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
22
States / cities
Riverside, California • San Diego, California • Wheat Ridge, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Not applicable Interventional

Mindful Breathing Awareness Through Pursed-Lip Breathing Training

NCT03198780
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Breathing Awareness
Other
Lead sponsor
Minnesota HealthSolutions
Industry
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease

NCT00862641
View directory record Official record
Conditions
Asthma, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
1,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
48
States / cities
Montgomery, Alabama • Anaheim, California • Encinitas, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 15, 2026, 9:27 AM EDT
Completed Phase 4 Interventional Results available

Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02786927
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA device, Placebo capsules for use in HANDIHALER device, Inhaler Preference Questionnaire Version 1, Inhaler Preference Questionnaire Version 2
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
22
States / cities
Glendale, Arizona • Clearwater, Florida • Orlando, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 15, 2026, 9:27 AM EDT